Northern LightRequest a Demo
Free buyer's guide · PDF, 21 pages

The Pharma & Biotech Buyer's Guide to Market & Competitive Intelligence Platforms

Shortlist pharma and biotech market and competitive intelligence platforms with 8 criteria, a demo checklist and the questions vendors struggle to answer: congress coverage and regulators beyond the FDA.

Rule out the wrong vendors early with 3 pass/fail tests
Test congress coverage and regulators beyond the FDA: Anvisa, NMPA, PMDA
Know what to insist on in a demo, and what to refuse
Cover of the Northern Light buyer's guide to market and competitive intelligence in pharma and biotech
Market and competitive intelligence in pharma and biotech
PDF, 21 pages

Get the free guide

Instant PDF download. We'll also send occasional research updates; unsubscribe anytime.

What is inside

Everything you need before the first vendor demo

01

What a platform has to be able to read

Breadth without depth is its own failure. A broad source set that has not been enriched for this industry is noise with good coverage, so a query about a mechanism of action has to return what a scientist means by it.

02

Ask about regulatory coverage twice

Most platforms are strongest on the FDA and thinner everywhere else. If your programs touch Brazil, China or Japan, name Anvisa, the NMPA and the PMDA, and ask what is covered today rather than what is planned.

03

Who has to be in the decision

An evaluation run by one person tends to produce a platform owned by one person, which is survivable until they move on. The guide names the five groups with a stake and when to bring each one in.

04

Eight criteria, three gates

Work them in order. The first three are pass or fail, and a platform that fails any of them is out regardless of its total, because none can be fixed after contract.

A look inside

Pages from the guide.

Page from the guide on the five groups with a stake in a pharma intelligence platform decisionPage from the guide showing the vendor scorecard with three gates and five scored criteria

“We were not short of information. We were short of one place to stand.”

Competitive intelligence lead, pharma

Questions the guide answers

What separates one market and competitive intelligence platform from another?

Every platform in this category has AI now, and every vendor says grounded and traceable. What separates market and competitive intelligence platforms is the licensed research the AI can legally reach, what the platform does when the evidence is thin, and whether an answer arrives in time to change the decision it was asked about.

How do you evaluate regulatory intelligence coverage in a competitive intelligence platform?

Most platforms are strongest on the FDA and thinner everywhere else. If your programs touch Brazil, China or Japan, name Anvisa, the NMPA and the PMDA in the evaluation and ask what is covered today rather than what is planned. A regulatory group that has to source its own content outside the platform will not use the platform.

Why does congress coverage matter when choosing a pharma intelligence platform?

Abstracts and posters are frequently the earliest public signal on a competitor program, and congress output is among the most heavily used material in pharma and biotech. Ask how many conferences are covered, how far back the archive runs, and what the process is when a congress you care about is not on the list.

Which criteria should decide a competitive intelligence platform evaluation?

Three of the eight are gates rather than scores: licensed content and scientific depth, what the platform does when coverage is thin, and governance and AI use rights. A platform that fails any of them is out regardless of its total, because none can be fixed after contract.

Who should be involved in a pharma intelligence platform evaluation?

Five groups have a stake: the person who will run the platform, the executive who will answer for it at renewal, whoever owns data and analytics, the teams who will read the output, and IT and security. Most evaluations involve one or two of them, which is how a platform ends up owned by one person.

Other editions

Not a pharma or biotech team?